Related Experiment Videos
[Clinical analysis of operation combined chemotherapy for stage IIIa non-small cell lung cancer]
Wei Wang1, Hui Li, Li-qun Shang
1Department of Thoracic Surgery, Naval General Hospital of People's Libration Army, Beijing 100037, China. wangyr02@hotmail.com
Objective:
To study the therapeutic result of operation combined chemotherapy for stage IIIa non-small cell lung cancer.
Methods:
From January 2000 to December 2003, the data of 83 cases with stage IIIa non-small cell lung cancer undergoing operation combined chemotherapy and 33 cases with stage IIIa non-small cell lung cancer undergoing non-operative therapy were retrospectively analyzed. The median survival time and the 1-, 2-, 3- year survival rates of the two groups were compared by the Kaplan-Meier method.
Results:
The median survival time of the operation group was 20.3 months, and the 1-, 2-, 3- year survival rates were 85%, 70%, and 35% respectively. The median survival time of the non-operation group was 14.5 months and the 1-, 2-, 3- year survival rates were 75%, 33%, and 15% respectively.
Conclusion:
The therapeutic result of the operation combined chemotherapy for the stage IIIa non-small cell lung cancer is better than that of the non-operative therapy obviously.
